Startseite Crystal structure of 3-(adamantan-1-yl)-1-(4-bromophenyl)urea, C17H21BrN2O
Artikel Open Access

Crystal structure of 3-(adamantan-1-yl)-1-(4-bromophenyl)urea, C17H21BrN2O

  • Fatmah A. M. Al-Omary , Lamees S. Al-Rasheed , Hazem A. Ghabbour und Ali A. El-Emam EMAIL logo
Veröffentlicht/Copyright: 8. Oktober 2016
Artikel downloaden (PDF)
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Zeitschrift für Kristallographie - New Crystal Structures
Aus der Zeitschrift Zeitschrift für Kristallographie - New Crystal Structures Band 232 Heft 1

Abstract

C17H21BrN2O, orthorhombic, Pna21 (no. 33), a = 9.2558(12) Å, b = 13.0186(17) Å, c = 13.4684(18) Å, V = 1622.9(4) Å3, Z = 4, Rgt(F) = 0.0471, wRref(F2) = 0.1059, T = 100 K.

CCDC no.:: 1473606

The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless blocks Size 0.49 × 0.22 × 0.18 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:25.3 cm−1
Diffractometer, scan mode:Bruker SMART, φ and ω
2θmax, completeness:55°, >99%
N(hkl)measured, N(hkl)unique3525, 3525
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 1934
N(param)refined:199
Programs:SHELX [25], Bruker programs [26]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
Br10.36803(8)0.67620(5)0.73438(7)0.1262(3)
O10.4429(3)0.2152(2)0.4914(2)0.0583(8)
N10.6674(4)0.1564(2)0.4538(3)0.0513(11)
N20.6388(4)0.3150(2)0.5210(3)0.0516(10)
C110.5742(3)0.2260(3)0.4884(3)0.0408(9)
C170.4583(4)0.3833(3)0.6352(3)0.0509(12)
H17A0.42260.31620.64800.061*
C120.5709(4)0.3975(3)0.5688(3)0.0398(10)
C10.5598(4)−0.0106(3)0.4993(3)0.0532(11)
H1A0.46750.02230.51850.064*
H1B0.6223−0.01430.55880.064*
C60.6339(3)0.0532(3)0.4190(3)0.0390(9)
C160.3977(5)0.4672(4)0.6831(4)0.0609(12)
H16A0.31920.45740.72760.073*
C130.6198(4)0.4966(3)0.5520(3)0.0509(11)
H13A0.69530.50790.50550.061*
C150.4501(6)0.5634(4)0.6667(4)0.0629(13)
C50.7776(4)0.0024(3)0.3932(4)0.0593(13)
H5A0.82730.04280.34110.071*
H5B0.84040.00080.45270.071*
C140.5608(5)0.5787(3)0.6016(4)0.0622(13)
H14A0.59700.64600.59060.075*
C20.5306(5)−0.1202(3)0.4595(4)0.0662(14)
H2A0.4799−0.16130.51170.079*
C70.4375(5)−0.1155(4)0.3679(5)0.0766(15)
H7A0.3436−0.08300.38400.092*
H7B0.4185−0.18580.34310.092*
C80.5140(6)−0.0536(4)0.2890(4)0.0759(15)
H8A0.4528−0.05120.22790.091*
C40.7517(5)−0.1064(4)0.3563(5)0.0779(17)
H4A0.8465−0.13880.33930.094*
C90.5387(5)0.0552(4)0.3265(4)0.0630(13)
H9A0.44470.08750.34250.076*
H9B0.58580.09660.27410.076*
C30.6766(6)−0.1704(4)0.4360(5)0.0858(17)
H3A0.7370−0.17310.49670.103*
H3B0.6618−0.24140.41200.103*
C100.6576(6)−0.1027(4)0.2641(4)0.097(2)
H10A0.7066−0.06250.21160.116*
H10B0.6417−0.17320.23890.116*
H1N10.744(4)0.171(2)0.467(2)0.017(9)*
H1N20.723(4)0.320(2)0.519(2)0.019(9)*

Source of material

4-Bromophenyl isocyanate (1.98 g, 0.01 mol) was added to a solution of 1-adamantylamine (1.51 g, 0.01 mol), in ethanol (10 mL), and the mixture was heated under reflux for 3 hours. On cooling, the precipitated crude product was filtered, dried and crystallized from ethanol to yield 3.11 g (89%) of the title compound (C17H21BrN2O) as transparent crystals. m.p.: 545–546 K. Single crystals were obtained by slow evaporation of a solution of the title compound in EtOH/CHCl3 (1:1) at room temperature. 1H NMR (DMSO-d6, 700.17 MHz): δ 1.62–1.64 (m, 6H, Adamantane-H), 2.03–2.05 (m, 6H, Adamantane-H), 2.08–2.10 (m, 3H, Adamantane-H), 5.90 (s, 1H, NH), 7.31–7.36 (m, 4H, Ar—H), 8.39 (s, 1H, NH). 13C NMR (DMSO-d6, 176.08 MHz): δ 29.35, 36.48, 42.06, 50.37 (Adamantane-C), 112.37, 119.68, 131.78, 140.51 (Ar—C), 154.17 (C = O). ESI-MS, m/z: 349.2 [M + 2H, 100%]−, 347.2 [M—H, 97%]−.

Experimental details

Carbon-bound hydrogen atoms were placed in calculated positions and were included in the refinement in the riding model approximation, with Uiso(H) set to 1.2Ueq(C). The N-bound hydrogen atoms were located on a difference Fourier map and refined freely.

Discussion

1,3-Disubstituted urea derivatives were early recognized as important leads possessing various biological activities. Various 1-(1-adamantyl)-3-substituted urea derivatives were identified as potent inhibitors of Mycobacterium tuberculosis epoxide hydrolase B , [1], [2], [3], [4]. In addition, several 1,3-disubstituted urea analogues were reported to exhibit marked anticancer , [5], [6], [7], [8], antifungal [9], antibacterial [10, 11], antiviral [12] and herbicidal [13] activities. On the other hand, adamantane derivatives were early proved to possess marked antiviral [14, 15], antimalarial [16], hypoglycemic [17], antitubercular [18] and central nervous [19, 20] avtivities. As a part of ongoing research project on chemotherapeutic [21, 22] and structural [23, 24] properties of adamantane derivatives, we report herein the crystal structure of the title adamantyl urea derivative.

The asymmetric unit of the title structure contains one molecule. The molecules are connected via two strong classical intermolecular hydrogen bonds, N1—H1N1⋯O1i and N2—H1N2⋯O1i. The H⋯A distances are 2.39(3) and 2.12(4) Å, respectively and the angles are 156(3) and 161(3)°, respectively. Symmetry codes: (i) x + 1/2, −y + 1/2, z.

Acknowledgements:

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding this work through the Research Group Project No. RG-1435-067.

References

1. Biswas, B. K.; Morisseau, C.; Garen, G.; Cherney, M. A.; Niu, C.; Hammock, B. D.; James, M. N. G.: The molecular structure of epoxide hydroxylase B from Mycobacterium tuberculosis and its complex with urea-based inhibitors. J. Mol. Biol. 381 (2008) 897–912.10.1016/j.jmb.2008.06.030Suche in Google Scholar PubMed PubMed Central

2. Brown, J. R.; North, E. J.; Hurdle, J. G.; Morisseau, C.; Scarborough, J. S.; Sun, D.; Korduláková, J.; Scherman, M. S.; Jones, V.; Grzegorzewicz, A.; Crew, R. M.; Jackson, M.; McNeil, M. R.; Lee, R. E.: The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg. Med. Chem. 19 (2011) 5585–5595.10.1016/j.bmc.2011.07.034Suche in Google Scholar PubMed PubMed Central

3. Scherman, M. S.; North, E. J.; Jones, V.; Hess, T. N.; Grzegorzewicz, A. E.; Kasagami, T.; Kim, I.-H.; Merzlikin, O.; Lenaerts, A. J.; Lee, R. E.; Jackson, M.; Morisseau, C.; McNeil, M. R.: Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. Bioorg. Med. Chem. 20 (2012) 3255–3262.10.1016/j.bmc.2012.03.058Suche in Google Scholar PubMed PubMed Central

4. North, E. J.; Scherman, M. S.; Bruhn, D. F.; Scarborough, J. S.; Maddox, M. M.; Jones, V.; Grzegorzewicz, A.; Yang, L.; Hess, T.; Morisseau, C.; Jackson, M.; McNeil, M. R.; Lee, R. E.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg. Med. Chem. 21 (2013) 2587–2599.10.1016/j.bmc.2013.02.028Suche in Google Scholar PubMed PubMed Central

5. Li, H. Q.; Yan, T.; Yang, Y.; Shi, L.; Zhou, C. F.; Zhu, H. L.: Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N'-phenylureas and thioureas as antitumor agents. Bioorg. Med. Chem. 18 (2010) 305–313.10.1016/j.bmc.2009.10.054Suche in Google Scholar PubMed

6. Song, E. Y.; Kaur, N.; Park, M. Y.; Jin, Y.; Lee, K.; Kim, G.; Lee, K. Y.; Yang, J. S.; Shin, J. H.; Nam, K. Y.; No, K. T.; Han, G.: Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor. Eur. J. Med. Chem. 43 (2008) 1519–1524.10.1016/j.ejmech.2007.10.008Suche in Google Scholar PubMed

7. Lu, C. S.; Tang, K.; Li, Y.; Jin, B.; Yin, D. L.; Ma, C.; Chen, X. G.; Huang, H. H.: Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib. Acta Pharm. Sinica 48 (2013) 709–717.Suche in Google Scholar

8. Ravez, S.; Arsenlis, S.; Barczyk, A.; Dupont, A.; Frédérick, R.; Hesse, S.; Kirsch, G.; Depreux, P.; Goossens, L.: Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors. Bioorg. Med. Chem. 23 (2015) 7340–7347.10.1016/j.bmc.2015.10.035Suche in Google Scholar PubMed

9. Kocyigit-Kaymakcioglu, B.; Celen, A. O.; Tabanca, N.; Ali, A.; Khan, S. I.; Khan, I. A.; Wedge, D. E.: Synthesis and biological activity of substituted urea and thiourea derivatives containing 1,2,4-triazole moieties. Molecules 18 (2013) 3562–3576.10.3390/molecules18033562Suche in Google Scholar PubMed PubMed Central

10. Gülkok, Y.; Bi cer, T.; Onurdaǧ, F. K.; Özgen, S.; Sahin, M. F.; Doǧruer, D. S.: Synthesis of some new urea and thiourea derivatives and evaluation of their antimicrobial activities. Turk. J. Chem. 36 (2012) 279–291.10.3906/kim-1106-54Suche in Google Scholar

11. Kaswala, P. B.; Chikhalia, K. H.; Shah, N. K.; Patel, D. P.; Patel, D. H.; Mudaliar, G. V.: Design, synthesis and antimicrobial evaluation of s-triazinyl urea and thiourea derivatives. ARKIVOC xi (2009) 326–335.10.3998/ark.5550190.0010.b30Suche in Google Scholar

12. Katla1, V. R.; Syed, R.; Golla, M.; Shaik, A.; Chamarthi, N. R.: Synthesis and biological evaluation of novel urea and thiourea derivatives of valaciclovir. J. Serb. Chem. Soc. 79 (2014) 283–289.10.2298/JSC120716095KSuche in Google Scholar

13. Yue, X. L.; Li, H.; Liu, S. S.; Zhang, Q. Y.; Yao, J. J.; Wang, F. Y.: N-Fluorinated phenyl-N'-pyrimidyl urea derivatives: Synthesis, biological evaluation and 3D-QSAR study. Chin. Chem. Lett. 25 (2014) 1069–1072.10.1016/j.cclet.2014.03.046Suche in Google Scholar

14. Rabinovich, S.; Baldini, J. T.; Bannister, R.: Treatment of influenza. The therapeutic efficacy of rimantadine HCl in a naturally occurring influenza A2 outbreak. Am. J. Med. Sci. 257 (1969) 328–335.10.1097/00000441-196905000-00005Suche in Google Scholar

15. Davies, W. L.; Grunnert, R. R.; Haff, R. F.; McGahen, J. W.; Neumeyer, E. M.; Paulshock, M.; Watts, J. C.; Wood, T. R.; Hermann, E. C.; Hoffmann, C. E.: Antiviral activity of 1-adamantamine (amantadine). Science 144 (1964) 862–863.10.1126/science.144.3620.862Suche in Google Scholar

16. Wang, X.; Dong, Y.; Wittlin, S.; Charman, S. A.; Chiu, F. C. K.; Chollet, J.; Katneni, K.; Mannila, J.; Morizzi, J.; Ryan, E.; Scheurer, C.; Steuten, J.; Tomas, J. S.; Snyder, C.; Vennerstrom, J. L.: Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres. J. Med. Chem. 56 (2013) 2547–2555.10.1021/jm400004uSuche in Google Scholar

17. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E.: 1-(3-Hydroxy-1-adamantyl)aminoacetyl-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 46 (2003) 2774–2789.10.1021/jm030091lSuche in Google Scholar

18. Jia, L.; Tomaszewski, J. E.; Hanrahan, C.; Coward, L.; Noker, P.; Gorman, G.; Nikonenko, B.; Protopopova, M.: Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Brit. J. Pharmacol. 144 (2005) 80–87.10.1038/sj.bjp.0705984Suche in Google Scholar

19. Bormann, J.: Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166 (1989) 59l–592.10.1016/0014-2999(89)90385-3Suche in Google Scholar

20. Abou-Gharbia, M. A.; Childers, W. E.; Fletcher, H.; McGaughey, G.; Patel, U.; Webb, M. B.; Yardley, J.; Andree, T.; Boast, C.; Kucharik, R. J.; Marquis, K.; Morris, H.; Scerni, R.; Moyer, J. A.: Synthesis and SAR of adatanserin: novel adamantly aryl- and heteroarylpiperazines with dual serotonin 5-HT1Aand 5-HT2 activity as potential anxiolytic and antidepressant agents. J. Med. Chem. 42 (1999) 5077–5094.10.1021/jm9806704Suche in Google Scholar PubMed

21. El-Emam, A. A.; Al-Tamimi, A.-M. S.; Al-Omar, M. A.; Al-Rashood, K. A.; Habib, E. E.: Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones. Eur. J. Med. Chem. 68 (2013) 96–102.10.1016/j.ejmech.2013.07.024Suche in Google Scholar PubMed

22. El-Emam, A. A.; Al-Deeb, O. A.; Al-Omar, M. A.; Lehmann, J.: Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg. Med. Chem. 12 (2004) 5107–5113.10.1016/j.bmc.2004.07.033Suche in Google Scholar PubMed

23. Al-Omary, F. A. M.; Mary, Y. S.; Panicker, C. Y.; El-Emam, A. A.; Al-Swaidan, I. A.; Al-Saadi, A. A.; Van Alsenoy, C.: Spectroscopic investigations, NBO, HOMO-LUMO, NLO analysis and molecular docking of 5-(adamantan-1-yl)-3-anilinomethyl-2,3-dihydro-1,3,4-oxadiazole-2-thione, a potential bioactive agent. J. Mol. Struct. 1096 (2015) 1–14.10.1016/j.molstruc.2015.03.049Suche in Google Scholar

24. Haress, N. G.; Al-Omary, F.; El-Emam, A. A.; Mary, Y. S.; Panicker, C. Y.; Al-Saadi, A. A.; War, J. A.; Van Alsenoy, C.: Spectroscopic investigation (FT-IR and FT-Raman), vibrational assignments, HOMO-LUMO analysis and molecular docking study of 2-(adamantan-1-yl)-5-(4-nitrophenyl)-1,3,4-oxadiazole. Spectrochim. Acta A 135 (2015) 973–983.10.1016/j.saa.2014.07.077Suche in Google Scholar PubMed

25. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

26. Bruker. APEX2, SAINT and SADABS. Brucker AXS Inc., Madison, Wisconsin, USA, 2009.Suche in Google Scholar

Received: 2016-4-13
Accepted: 2016-9-25
Published Online: 2016-10-8
Published in Print: 2017-1-1

©2016 Fatmah A. M. Al-Omary et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Editorial
  3. Twenty years of crystal structure publication and the road ahead
  4. Crystal Structures
  5. Crystal structure of poly-[triaqua-(μ4-5′-carboxy-[1,1′-biphenyl]-2,3,3′-tricarboxylate-κ6O1,O2:O3,O4:O5:O6)praseodymium(III), C16H13O11Pr
  6. Crystal structure of (R)-1-(2,3-dihydro-1H-pyrrolizin-5-yl)-2,3-dihydroxypropan-1-one, C10H13NO3
  7. Crystal structure of (E)-4-nitro-2-((2-phenoxyphenylimino)methyl)phenol, C19H14N2O4
  8. Crystal structure of 3,3′-di(furan-2-yl)-5,5′-bi-1,2,4-triazine
  9. Crystal structure of 11-(p-coumaroyloxy)-tremetone, C22H20O5
  10. The crystal structure of 1,3-bis(2,6-diiso-propylphenyl)imidazol-2-ylidene)-dibromido-(1-methyl-1H-imidazole-κ1N)palladium(II) – ethyl acetate – water (1/1/1), C31H42Br2N4Pd
  11. Crystal structure of 2-((3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1H-indene-1,3(2H)-dione, C28H19N5O2
  12. Crystal structure of 2-(5-(4-fluorophenyl)-3-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)-4-(5-methyl-1-p-tolyl-1H-1,2,3-triazol-4-yl)thiazole, C29H25FN6S
  13. Crystal structure of poly-[aqua-(μ7-benzene-1,3,5-tricarboxylato)-(μ3-1,2,4-triazol-1-ido)dicobalt(II)], C11H7Co2N3O7
  14. Crystal constructure of 16(S)-methyl-6α-carboxy-1, 15-dioxo-6, 7-seco-ent-kaur-2-en-7, 20-olide, C20H24O6
  15. Crystal structure of 1-(benzo[d]thiazol-2-yl)-3-phenylthiourea, C14H11N3S2
  16. Crystal structure of 3-(2-bromophenyl)-1,1-dimethylthiourea, C9H11BrN2S
  17. Crystal structure of 1-(adamantan-1-yl)-3-(3-chlorophenyl)thiourea, C17H21ClN2S
  18. Crystal structure of 3-(adamantan-1-yl)-1-(4-bromophenyl)urea, C17H21BrN2O
  19. Crystal structure of (Z)-Ethyl 2-cyano-2-(3-phenylthiazolidin-2-ylidene) acetate, C14H14N2O2S
  20. Crystal structure of methyl 2b-ethyl-1a,2a,2b,2b1,3,5,10,11-octahydro-1H-oxireno[2′,3′:6,7]indolizino[8,1-cd]carbazole-4-carboxylate, C21H24N2O3
  21. Crystal structure of 2-amino-5-oxo-4-(3,4,5-trimethoxy-phenyl)-4,5,6,7-tetrahydro-cyclopenta[b]pyran-3-carbonitrile, C18H18N2O5
  22. Crystal structure of 1,2,3-trimethyl-2,3-dihydro-1H-perimidine, C14H16N2
  23. Crystal structure of bis(2,6-dihydroxymethyl)pyridine-κ3N,O,O′)-bis(μ2-6-chloropyridin-2-olato-κ3N,O:O)-bis(6-chloropyridin-2-olato-κO)-bis(nitrato-κ2O,O′)digadolinium(III), C34H30Cl4Gd2N8O14
  24. Crystal structure of 8-isopropyl-8-aza-bicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate, C19H27NO3
  25. Crystal structure of 1-methyl-3-[((naphthalen-2-ylsulfonyl)oxy)imino]indolin-2-one, C19H14N2O4S
  26. Crystal structure (7,8-bis(diisopropylphosphino)-7,8-dicarba-nido-undecaborane-κ2P,P′)-(benzoato-κ2O,O′)nickel(II), C21H42B9NiO2P2
  27. Crystal structure of methyl-2-methyl-4-(2-oxo-2-phenylethyl)-5-phenyl-1H-pyrrole-3-carboxylate, C21H19NO3
  28. Crystal structure of 2-[(2-oxo-thiazolidine-3-carbonyl)sulfamoyl]-methy-benzoic acid methyl ester, C13H14N2O6S2
  29. Crystal structure of N′-(2-phenylacetyl)thiophene-2-carbohydrazide monohydrate, C13H14N2O3S
  30. Crystal structure of 1,1′-(hexane-1,6-diyl)bis(3-methyl-1H-imidazol-3-ium) bis(hexafluoro phosphate), C14H24F12N4P2
  31. Crystal structure of di-μ-chlorido-bis[1,2-bis(dicyclohexylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]zinc(II), C52H108B20Cl2P4Zn2
  32. Crystal structure of dibromido-bis[μ-1-[(2-methyl-1H-benzoimidazol-1-yl)methyl]-1H-benzotriazole-κN]mercury(II), C30H26Br2HgN10
  33. Crystal structure of bis(μ-nitrato-κ2O:O)-bis[1,2-bis(diphenylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]disilver(I) dicloromethane monosolvate, C54H64B20Cl4O6P4Ag2
  34. Crystal structure of dinuclear dichloridobis(dimethylformamide-kO)bis[μ2-3-(2-oxyphenyl)-5-(pyrazin-2-yl)-1,2,4-triazol-1ido-κ4-O,N:N′,N′′(2−)]diiron(III) − dimethylformamide (1/1), C36H42Cl2Fe2N14O6
  35. Crystal structure of diaqua-dinitrato-κO-bis(4-(1H-pyrazol-3-yl)pyridine-κN)manganese(II), C16H18MnN8O8
  36. Crystal structure of (Z)-6-methoxy-2-(2,2,2-trifluoro-1-hydroxyethylidene)-2,3-dihydro-1H-inden-1-one, C12H6F6O3
  37. Crystal Structure of 4-(2-chloroacetamido)pyridinium chloride monohydrate, C7H10Cl2N2O2
  38. Crystal structure of 2-amino-4-(4-chloro-phenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13ClN2O2
  39. Crystal structure of (E)-1-(2-(thiophen-2-ylmethylene)hydrazinyl)phthalazine hydrochloride–ethanol (1/1), C15H17ClN4OS
  40. Crystal structure of N,N-diethyl-5-bromo-3,4-dihydro-2,4-dioxopyrimidine-1(2H)-carboxamide, C9H12BrN3O3
  41. Crystal structure of 3-(2-(4-chlorophenyl)-3-hydroxy-3,3-diphenylpropyl)-1,1-dimethylurea, C24H25ClN2O2
  42. Crystal structure of 3-(4-chlorophenyl)-1,1-dimethylthiourea, C9H11ClN2S
  43. Crystal structure of 2-amino-4-(4-bromo-phenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C16H11BrN2O3
  44. Crystal structure of 4-(3,4-dimethyl-phenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester, C21H25NO3
  45. Crystal structure of (E)-2-({4-hydroxy-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl} methylidene)-1-indanone, C23H26N2O3
  46. Crystal structure of tripropylammonium 2′-carboxy-[1,1′-biphenyl]-2-carboxylate – [1,1′-biphenyl]-2,2′-dicarboxylic acid (2/1), C60H72N2O12
  47. Crystal structure of catena-poly-{aqua-[μ2-1,2-bis((1H-imidazol-1-yl)methyl)benzene-κ2N:N′]-[μ2-4,4′-(dimethylsilanediyl)dibenzato-κ3O,O′:O′]nickel(II)}, C30H30N4NiO5Si
  48. The crystal structure of 1-(4-bromophenyl)-2-(4-(4-fluorophenyl)piperazin-1-yl)ethanol, C18H20BrFN2O1
  49. Crystal structure of trimethylammonium 4-((4-carboxyphenyl)sulfonyl)benzoate, C17H19NO6S
  50. Crystal structure of syn-2,4-di-o-tolylpentane-2,4-diol, C19H24O2
  51. Crystal structure of 2-[3,5-bis(trifluoromethyl)benzylsulfanyl]-5-(5-bromothiophen-2-yl)-1,3,4-oxadiazole, C15H7BrF6N2OS2
  52. Crystal structure of (E)-3-((naphthalen-1-ylimino)methyl)-4-nitrophenol, C17H12N2O3
  53. Crystal structure of 2-dichloromethyl-2-p-nitrophenyl-1,3-dioxolane, C10H9Cl2NO4
  54. Crystal structure of (1,4,8,11-tetraazacyclotetradecane)palladium(II) tetracyanopalladate(II), C14H24N8Pd2
  55. Crystal structure of 2-(4-oxo-2-thioxothiazolidin-3-yl)acetic acid monohydrate, C5H7NO4S2
  56. Crystal structure of a P4-bridged (η5-pentamethyl-cyclopentadienyl)(η5-adamantylcyclopentadienyl) titanium(III)complex, C50H66P4Ti2
  57. Crystal structure of cis-bis(2,2′-bipyrimidine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C18H12N10NiS2
  58. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)dibromidomanganese(II), C20H16Br2MnN4
  59. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C22H16N6NiS2
  60. Crystal structure of trans-dibromido(1,4,8,11-tetraazacyclotetradecane)nickel(II), C10H24Br2N4Ni
  61. Crystal structure of cis-tetrabromidobis(pyridine-κN)platinum(IV), C10H10Br4N2Pt
  62. Crystal structure of (E)-5-((4-chlorophenyl)diazenyl)-2-(5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-methylthiazole, C23H17ClFN5S2
  63. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridocobaltate(II) monohydrate, C10H18Cl4CoN2O
https://doi.org/10.1515/ncrs-2016-0118
Creative Commons
BY-NC-ND 3.0

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Editorial
  3. Twenty years of crystal structure publication and the road ahead
  4. Crystal Structures
  5. Crystal structure of poly-[triaqua-(μ4-5′-carboxy-[1,1′-biphenyl]-2,3,3′-tricarboxylate-κ6O1,O2:O3,O4:O5:O6)praseodymium(III), C16H13O11Pr
  6. Crystal structure of (R)-1-(2,3-dihydro-1H-pyrrolizin-5-yl)-2,3-dihydroxypropan-1-one, C10H13NO3
  7. Crystal structure of (E)-4-nitro-2-((2-phenoxyphenylimino)methyl)phenol, C19H14N2O4
  8. Crystal structure of 3,3′-di(furan-2-yl)-5,5′-bi-1,2,4-triazine
  9. Crystal structure of 11-(p-coumaroyloxy)-tremetone, C22H20O5
  10. The crystal structure of 1,3-bis(2,6-diiso-propylphenyl)imidazol-2-ylidene)-dibromido-(1-methyl-1H-imidazole-κ1N)palladium(II) – ethyl acetate – water (1/1/1), C31H42Br2N4Pd
  11. Crystal structure of 2-((3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1H-indene-1,3(2H)-dione, C28H19N5O2
  12. Crystal structure of 2-(5-(4-fluorophenyl)-3-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)-4-(5-methyl-1-p-tolyl-1H-1,2,3-triazol-4-yl)thiazole, C29H25FN6S
  13. Crystal structure of poly-[aqua-(μ7-benzene-1,3,5-tricarboxylato)-(μ3-1,2,4-triazol-1-ido)dicobalt(II)], C11H7Co2N3O7
  14. Crystal constructure of 16(S)-methyl-6α-carboxy-1, 15-dioxo-6, 7-seco-ent-kaur-2-en-7, 20-olide, C20H24O6
  15. Crystal structure of 1-(benzo[d]thiazol-2-yl)-3-phenylthiourea, C14H11N3S2
  16. Crystal structure of 3-(2-bromophenyl)-1,1-dimethylthiourea, C9H11BrN2S
  17. Crystal structure of 1-(adamantan-1-yl)-3-(3-chlorophenyl)thiourea, C17H21ClN2S
  18. Crystal structure of 3-(adamantan-1-yl)-1-(4-bromophenyl)urea, C17H21BrN2O
  19. Crystal structure of (Z)-Ethyl 2-cyano-2-(3-phenylthiazolidin-2-ylidene) acetate, C14H14N2O2S
  20. Crystal structure of methyl 2b-ethyl-1a,2a,2b,2b1,3,5,10,11-octahydro-1H-oxireno[2′,3′:6,7]indolizino[8,1-cd]carbazole-4-carboxylate, C21H24N2O3
  21. Crystal structure of 2-amino-5-oxo-4-(3,4,5-trimethoxy-phenyl)-4,5,6,7-tetrahydro-cyclopenta[b]pyran-3-carbonitrile, C18H18N2O5
  22. Crystal structure of 1,2,3-trimethyl-2,3-dihydro-1H-perimidine, C14H16N2
  23. Crystal structure of bis(2,6-dihydroxymethyl)pyridine-κ3N,O,O′)-bis(μ2-6-chloropyridin-2-olato-κ3N,O:O)-bis(6-chloropyridin-2-olato-κO)-bis(nitrato-κ2O,O′)digadolinium(III), C34H30Cl4Gd2N8O14
  24. Crystal structure of 8-isopropyl-8-aza-bicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate, C19H27NO3
  25. Crystal structure of 1-methyl-3-[((naphthalen-2-ylsulfonyl)oxy)imino]indolin-2-one, C19H14N2O4S
  26. Crystal structure (7,8-bis(diisopropylphosphino)-7,8-dicarba-nido-undecaborane-κ2P,P′)-(benzoato-κ2O,O′)nickel(II), C21H42B9NiO2P2
  27. Crystal structure of methyl-2-methyl-4-(2-oxo-2-phenylethyl)-5-phenyl-1H-pyrrole-3-carboxylate, C21H19NO3
  28. Crystal structure of 2-[(2-oxo-thiazolidine-3-carbonyl)sulfamoyl]-methy-benzoic acid methyl ester, C13H14N2O6S2
  29. Crystal structure of N′-(2-phenylacetyl)thiophene-2-carbohydrazide monohydrate, C13H14N2O3S
  30. Crystal structure of 1,1′-(hexane-1,6-diyl)bis(3-methyl-1H-imidazol-3-ium) bis(hexafluoro phosphate), C14H24F12N4P2
  31. Crystal structure of di-μ-chlorido-bis[1,2-bis(dicyclohexylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]zinc(II), C52H108B20Cl2P4Zn2
  32. Crystal structure of dibromido-bis[μ-1-[(2-methyl-1H-benzoimidazol-1-yl)methyl]-1H-benzotriazole-κN]mercury(II), C30H26Br2HgN10
  33. Crystal structure of bis(μ-nitrato-κ2O:O)-bis[1,2-bis(diphenylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]disilver(I) dicloromethane monosolvate, C54H64B20Cl4O6P4Ag2
  34. Crystal structure of dinuclear dichloridobis(dimethylformamide-kO)bis[μ2-3-(2-oxyphenyl)-5-(pyrazin-2-yl)-1,2,4-triazol-1ido-κ4-O,N:N′,N′′(2−)]diiron(III) − dimethylformamide (1/1), C36H42Cl2Fe2N14O6
  35. Crystal structure of diaqua-dinitrato-κO-bis(4-(1H-pyrazol-3-yl)pyridine-κN)manganese(II), C16H18MnN8O8
  36. Crystal structure of (Z)-6-methoxy-2-(2,2,2-trifluoro-1-hydroxyethylidene)-2,3-dihydro-1H-inden-1-one, C12H6F6O3
  37. Crystal Structure of 4-(2-chloroacetamido)pyridinium chloride monohydrate, C7H10Cl2N2O2
  38. Crystal structure of 2-amino-4-(4-chloro-phenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13ClN2O2
  39. Crystal structure of (E)-1-(2-(thiophen-2-ylmethylene)hydrazinyl)phthalazine hydrochloride–ethanol (1/1), C15H17ClN4OS
  40. Crystal structure of N,N-diethyl-5-bromo-3,4-dihydro-2,4-dioxopyrimidine-1(2H)-carboxamide, C9H12BrN3O3
  41. Crystal structure of 3-(2-(4-chlorophenyl)-3-hydroxy-3,3-diphenylpropyl)-1,1-dimethylurea, C24H25ClN2O2
  42. Crystal structure of 3-(4-chlorophenyl)-1,1-dimethylthiourea, C9H11ClN2S
  43. Crystal structure of 2-amino-4-(4-bromo-phenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C16H11BrN2O3
  44. Crystal structure of 4-(3,4-dimethyl-phenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester, C21H25NO3
  45. Crystal structure of (E)-2-({4-hydroxy-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl} methylidene)-1-indanone, C23H26N2O3
  46. Crystal structure of tripropylammonium 2′-carboxy-[1,1′-biphenyl]-2-carboxylate – [1,1′-biphenyl]-2,2′-dicarboxylic acid (2/1), C60H72N2O12
  47. Crystal structure of catena-poly-{aqua-[μ2-1,2-bis((1H-imidazol-1-yl)methyl)benzene-κ2N:N′]-[μ2-4,4′-(dimethylsilanediyl)dibenzato-κ3O,O′:O′]nickel(II)}, C30H30N4NiO5Si
  48. The crystal structure of 1-(4-bromophenyl)-2-(4-(4-fluorophenyl)piperazin-1-yl)ethanol, C18H20BrFN2O1
  49. Crystal structure of trimethylammonium 4-((4-carboxyphenyl)sulfonyl)benzoate, C17H19NO6S
  50. Crystal structure of syn-2,4-di-o-tolylpentane-2,4-diol, C19H24O2
  51. Crystal structure of 2-[3,5-bis(trifluoromethyl)benzylsulfanyl]-5-(5-bromothiophen-2-yl)-1,3,4-oxadiazole, C15H7BrF6N2OS2
  52. Crystal structure of (E)-3-((naphthalen-1-ylimino)methyl)-4-nitrophenol, C17H12N2O3
  53. Crystal structure of 2-dichloromethyl-2-p-nitrophenyl-1,3-dioxolane, C10H9Cl2NO4
  54. Crystal structure of (1,4,8,11-tetraazacyclotetradecane)palladium(II) tetracyanopalladate(II), C14H24N8Pd2
  55. Crystal structure of 2-(4-oxo-2-thioxothiazolidin-3-yl)acetic acid monohydrate, C5H7NO4S2
  56. Crystal structure of a P4-bridged (η5-pentamethyl-cyclopentadienyl)(η5-adamantylcyclopentadienyl) titanium(III)complex, C50H66P4Ti2
  57. Crystal structure of cis-bis(2,2′-bipyrimidine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C18H12N10NiS2
  58. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)dibromidomanganese(II), C20H16Br2MnN4
  59. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C22H16N6NiS2
  60. Crystal structure of trans-dibromido(1,4,8,11-tetraazacyclotetradecane)nickel(II), C10H24Br2N4Ni
  61. Crystal structure of cis-tetrabromidobis(pyridine-κN)platinum(IV), C10H10Br4N2Pt
  62. Crystal structure of (E)-5-((4-chlorophenyl)diazenyl)-2-(5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-methylthiazole, C23H17ClFN5S2
  63. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridocobaltate(II) monohydrate, C10H18Cl4CoN2O
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 5.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0118/html
Button zum nach oben scrollen